Operating revenue: | |
Personalized oncology solutions | 511K |
Translational oncology solutions | 3.16M |
Total operating revenue | 3.67M |
Costs and operating expenses: | |
Cost of personalized oncology solutions | 474K |
Cost of translational oncology solutions | 2.05M |
Research and development | 1.21M |
Sales and marketing | 925K |
General and administrative | 1.53M |
Total costs and operating expenses | 6.19M |
Loss from operations | -2.52M |
Other income (expense): | |
Change in fair value of warrant liability | |
Other income | |
Total other income | -9K |
Loss before provision for income taxes | -2.53M |
Provision for income taxes | 14K |
Net loss | -2.55M |
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) | -0.26 |
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) |